An Lc-Ms/Ms Method Development and Validation for the Quantification of Lurbinectedin in Biological Matrices; Application to Kinetic Study in Rabbits
DOI:
https://doi.org/10.22159/ijap.2026v18i5.56764Keywords:
Lurbinectedin, Cancers, LC–MS/MS, Validation, Precision and LinearityAbstract
Objective: The primary objective of the present research was to develop an accurate liquid chromatography and tandem mass spectrometry (LC-MS/MS) technique utilizing electrospray ionization for the quantification of Lurbinectedin in biological matrices.
Methods: The components were isolated using chromatographic techniques on a Hypersil Gold (50mm × 4.6 mm, 5µ) C18 column. The volume of injection was established at 5μL. The column oven temperature and flow rate were maintained at 25°C and 0.50 mL/min, respectively. Isocratic method of separation was executed with a mobile phase composition of formic acid (0.1%), acetonitrile, and methanol in a ratio of 10:20:70 (%v/v/v).
Results: In the context of multiple reaction monitoring, the observed fragments and product ions findings were recorded at m/z 785.28/174.09 for Lurbinectedin and 450.11→257.10 for the Asciminib internal standard. The linearity graph for the drug exhibited anr2 value exceeding 0.99 and demonstrated a rectilinear relationship across the concentrations in between 0.01 and 200ng/mL. Precision findings within a single day ranged from %RSD of 3.12% to 4.85%, while across different experimental days, precision values varied between 2.96% and 5.01%. The average Lurbinectedin recoveries ranged between 93.83% to 102.36% at three quality control levels.
Conclusion: The findings regarding accuracy, specificity, sensitivity, matrix effect, recovery and stability findings of Lurbinectedin in plasma samples for the established method highlight its significance in bioequivalence and pharmacokinetic studies.
References
1. Takahashi R, Mabuchi S, Kawano M, Sasano T, Matsumoto Y, Kuroda H. Preclinical investigations of PM01183 (lurbinectedin) as a single agent or in combination with other anticancer agents for clear cell carcinoma of the ovary. PLoS One. 2016;11(3):e0151050. doi:10.1371/journal.pone.0151050.
2. Paz-Ares LG, Trigo Perez JM, Besse B, Moreno V, Lopez R, Sala MA, et al. Efficacy and safety profile of lurbinectedin in second-line SCLC patients: results from a phase II single-agent trial. J Clin Oncol. 2019;37(15 Suppl):8506. doi:10.1200/JCO.2019.37.15_suppl.8506.
3. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51. doi:10.1016/j.cell.2010.03.014.
4. Engblom C, P firschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16(7):447-462. doi:10.1038/nrc.2016.54.
5. U.S. Food and Drug Administration (FDA). Lurbinectedin orphan drug designation and approval. Silver Spring (MD): FDA; 2018 Aug 1 [cited 2020 Jun 16]. Available from: https://www.fda.gov
6. Johnson K. FDA approves lurbinectedin combo for ES-SCLC maintenance [Internet]. Medscape. 2025 May 26 [cited 2025 Oct 10]. Available from: Medscape article.
7. King N, Garcia-Martinez S, Alcaraz E, Grisalena A, Lubomirov R, Altares R, et al. Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS. PLoS One. 2023;18(3):e0283783. doi:10.1371/journal.pone.0283783.
8. Van Andel L, Rosing H, Lubomirov R, Avilés P, Fudio S, Tibben MM, et al. Development and validation of a liquid chromatography–tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine. J Pharm Biomed Anal. 2018;158:160-165. doi:10.1016/j.jpba.2018.05.053.
9. Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, Galmarini CM, Núñez R, Kahatt C, et al. ATLANTIS: a phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future Oncol. 2019;15(3):231-239. doi:10.2217/fon-2018-0597.
10. Calvo E, Moreno V, Flynn M, Holgado E, Olmedo ME, Lopez Criado MP, et al. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study. Ann Oncol. 2017;28(10):2559-2566. doi:10.1093/annonc/mdx357.
11. European Medicines Agency. Guideline on bioanalytical method validation. London (UK): EMA; 2011.
12. U.S. Food and Drug Administration. Guidance for industry: bioanalytical method validation. Rockville (MD): CDER, CVM; 2001 May.
13. International Conference on Harmonisation (ICH). Validation of analytical procedures: text and methodology Q2(R1). Geneva (Switzerland): ICH; 2005.
14. Sai Uday Kiran G, Sandhya P, Shankar CH, Bhikshapathi DVRN, Mamatha P. LC–MS/MS quantification method development and validation for dabrafenib in biological matrices. J Appl Pharm Sci. 2023;13(1):180-186. doi:10.7324/JAPS.2023.130120.
15. Dadhaniya T, Chaudhary K, Mehta P. Development of LC-MS/MS method for determination of iloperidone in rabbit plasma: application to a pharmacokinetic study. Int J Pharm Pharm Sci. 2013;7(4):294-297.
16. Lolla S, Gubbiyappa KS, Cheruku S, Bhikshapathi DVRN. Validation of an LC-MS/MS method for quantitation of fostemsavir in plasma. J Pharmacol Toxicol Methods. 2023;120:107254. doi:10.1016/j.vascn.2023.107254.
17. Puttagunta SB, Shaik RP, Bannoth CK, Challa BSR, Awen BZS. Bioanalytical method for quantification of solifenacin in rat plasma by LC-MS/MS and its application to pharmacokinetic study. J Anal Sci Technol. 2014;5(1):35. doi:10.1186/s40543-014-0035-0.
18. Fan X, Yang G, Cui W, Liu Q, Zhang Z, Zhang Z. Development and full validation of an LC-MS/MS methodology to quantify capmatinib (INC280) following intragastric administration to rats. Biomed Chromatogr. 2020;34(3): e4768. doi:10.1002/bmc.4768.
19. Saraner N, Karagoz A, Guney B, Saglam O. Determination of dasatinib in human plasma using liquid chromatography–tandem mass spectrometry. Int J Anal Bioanal Methods. 2019; 1:2.
20. Sellappan M, Devakumar D. Development and validation of RP-HPLC method for estimation of escitalopram oxalate and flupentixol dihydrochloride in combined dosage form and plasma. Int J Pharm Pharm Sci. 2021;13(2):61-66. doi:10.22159/ijpps.2021v13i2.30158.
21. Gurav P, Damle M. Bioanalytical method for estimation of teriflunomide in human plasma. Int J Pharm Pharm Sci. 2022;14(9):19-23. doi:10.22159/ijpps.2022v14i9.45151.
22. Shankar CH, Bhikshapathi D, Medipalli V, Arjuna RN, Sadasivam RK. Bioanalytical method development and validation for quantitation of larotrectinib in human plasma: application to pharmacokinetics in healthy rabbits. J Appl Pharm Sci. 2023;13(11):111-118. doi:10.7324/JAPS.2023.127799.
Published
How to Cite
Issue
Section
Copyright (c) 2026 PALAKOLLU D. S. SANKAR, NARESH PANIGRAHI
This work is licensed under a Creative Commons Attribution 4.0 International License.